03/20/2017 - 12:57pm

Rob Easley, who joined the convenience store and pharmacy chain in February, replaces longtime VP of sales of marketing, John Schaninger. 

03/20/2017 - 12:40pm

Twix is rolling out packaging for its customers who can’t decide which Twix they prefer — left or right — and it has TV and online advertising planned to support the launch. 

03/20/2017 - 12:22pm

Coty’s VP creative and integrated communications, Sam Southey, said that selecting a new creative agency is part of Coty’s strategy to drive a new level of insights and consumer engagement in the aftermath of the company’s merger with Procter &  Gamble’s specialty beauty business. 

03/20/2017 - 12:14pm

The authorized generic is an estrogen/progestin combined oral contraceptive indicated for use by women to prevent pregnancy.

03/20/2017 - 11:58am

The drug is approved in Mexico for the treatment of low blood pressure and heart failure.

03/20/2017 - 11:29am

Entresto lowered HbA1c levels — a measure of average blood glucose levels for the past two to three months — after one year of treatment for heart failure, according to Novartis-funded research.

03/17/2017 - 4:20pm

BayCare branded telehealth sites will appear in various Publix locations, BayCare screening stations will be in all Publix locations, and Publix pharmacies onsite will be at five BayCare hospital locations.

03/17/2017 - 4:03pm

CVS Pharmacy is keeping up with beauty trends with plans to bring four tough-to-find brands to its shelves this spring, several of which will be CVS exclusives. 

03/17/2017 - 3:31pm
Based on new data about Amgen’s PCSK9 inhibitor cholesterol drug Repatha, CVS Health’s chief medical officer, Dr. Troyen Brennan, told Reuters that the number of patients eligible to use the drug could quadruple. He noted that the data — published in the New England Journal of Medicine and showing Repatha’s ability to reduce heart attack, stroke, heart disease deaths, chest pain hospitalizations and stent and bypass procedures by 15% — would need to be reviewed by heart experts. (Reuters)